tradingkey.logo

Femasys Inc

FEMY
0.835USD
+0.151+22.17%
Close 11/05, 16:00ETQuotes delayed by 15 min
27.20MMarket Cap
LossP/E TTM

Femasys Inc

0.835
+0.151+22.17%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Femasys Inc

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite strong stock market performance and technicals, the fundamentals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Femasys Inc's Score

Industry at a Glance

Industry Ranking
126 / 210
Overall Ranking
283 / 4616
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 3 analysts
Buy
Current Rating
5.667
Target Price
+729.07%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Femasys Inc Highlights

StrengthsRisks
Femasys Inc. is a biomedical company. The Company is focused on addressing unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. The Company also developed a technology platform, namely FemEMB for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 35.06% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.63M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 1.63M.
Fairly Valued
The company’s latest PE is -0.98, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 6.07M shares, increasing 18.36% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 951.87K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.15.

Financial Health

Currency: USD Updated: 2025-11-05

The company's current financial score is 5.38, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 409.27K, representing a year-over-year increase of 84.78%, while its net profit experienced a year-over-year increase of 2.11%.

Score

Industry at a Glance

Previous score
5.38
Change
0

Financials

5.03

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

7.66

Operational Efficiency

2.57

Growth Potential

4.55

Shareholder Returns

7.11

Femasys Inc's Company Valuation

Currency: USD Updated: 2025-11-05

The company’s current valuation score is 6.05, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -0.98, which is -67.43% below the recent high of -0.32 and -306.89% above the recent low of -3.97.

Score

Industry at a Glance

Previous score
6.05
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 126/210
No Data

Earnings Forecast

Currency: USD Updated: 2025-11-05

The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Femasys Inc is 6.00, with a high of 8.00 and a low of 3.00.

Score

Industry at a Glance

Previous score
8.00
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts
Buy
Current Rating
5.667
Target Price
+729.07%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

110
Total
7
Median
9
Average
Company name
Ratings
Analysts
Femasys Inc
FEMY
3
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
32
Zimmer Biomet Holdings Inc
ZBH
30
Dexcom Inc
DXCM
30
1
2
3
...
22

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-05

The company’s current price momentum score is 8.50, which is higher than the Healthcare Equipment & Supplies industry's average of 6.82. Sideways: Currently, the stock price is trading between the resistance level at 0.98 and the support level at 0.60, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.94
Change
1.56

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(0)
Neutral(1)
Buy(3)
Indicators
Value
Direction
MACD(12,26,9)
0.017
Buy
RSI(14)
65.126
Neutral
STOCH(KDJ)(9,3,3)
58.862
Buy
ATR(14)
0.123
Low Volatility
CCI(14)
206.985
Overbought
Williams %R
19.118
Overbought
TRIX(12,20)
1.197
Buy
StochRSI(14)
100.000
Overbought
Moving Average
Sell(1)
Neutral(0)
Buy(5)
Indicators
Value
Direction
MA5
0.687
Buy
MA10
0.667
Buy
MA20
0.644
Buy
MA50
0.504
Buy
MA100
0.674
Buy
MA200
0.954
Sell

Institutional Confidence

Currency: USD Updated: 2025-11-05

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.40. The latest institutional shareholding proportion is 14.12%, representing a quarter-over-quarter decrease of 47.47%. The largest institutional shareholder is The Vanguard, holding a total of 951.87K shares, representing 2.21% of shares outstanding, with 37.40% decrease in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Chernett (Jorey)
3.03M
+86.81%
Dauntless Investment Group, LLC
2.32M
+47.34%
Uzialko (Edward R Jr.)
1.22M
--
The Vanguard Group, Inc.
Star Investors
951.87K
+15.28%
Alumni Capital Management LLC
931.90K
--
Lee-Sepsick (Kathy)
432.85K
+12.63%
Clear Creek Financial Management, LLC
281.82K
+4.23%
Geode Capital Management, L.L.C.
251.39K
+2.40%
CM Management, LLC
225.00K
-47.06%
UBS Financial Services, Inc.
122.33K
--
1
2

Risk Assessment

Currency: USD Updated: 2025-11-05

The company’s current risk assessment score is 1.36, which is lower than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is -2.54. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
1.36
Change
0
Beta vs S&P 500 index
-2.54
VaR
--
240-Day Maximum Drawdown
+80.54%
240-Day Volatility
+134.74%

Return

Best Daily Return
60 days
+51.87%
120 days
+51.87%
5 years
--
Worst Daily Return
60 days
-27.00%
120 days
-27.00%
5 years
--
Sharpe Ratio
60 days
+1.01
120 days
+0.34
5 years
--

Risk Assessment

Maximum Drawdown
240 days
+80.54%
3 years
+91.15%
5 years
--
Return-to-Drawdown Ratio
240 days
-0.07
3 years
-0.07
5 years
--
Skewness
240 days
+2.26
3 years
+15.45
5 years
--

Volatility

Realised Volatility
240 days
+134.74%
5 years
--
Standardised True Range
240 days
+10.50%
5 years
--
Downside Risk-Adjusted Return
120 days
+64.83%
240 days
+64.83%
Maximum Daily Upside Volatility
60 days
+228.39%
Maximum Daily Downside Volatility
60 days
+118.77%

Liquidity

Average Turnover Rate
60 days
+2.49%
120 days
+2.06%
5 years
--
Turnover Deviation
20 days
+15.29%
60 days
-45.64%
120 days
-54.93%

Peer Comparison

Healthcare Equipment & Supplies
Femasys Inc
Femasys Inc
FEMY
5.99 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Castle Biosciences Inc
Castle Biosciences Inc
CSTL
8.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AxoGen Inc
AXGN
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
TCMD
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Zimmer Biomet Holdings Inc
Zimmer Biomet Holdings Inc
ZBH
8.54 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI